Can gut microbial overgrowth alter B-vitamin availability and urinary organic-acid markers indicate dysbiosis?

Nutritional and metabolic impacts of microbial overgrowth

• B-vitamin alteration: Small intestinal bacterial overgrowth (SIBO) significantly disrupts host B-vitamin dynamics. Overgrowing anaerobic bacteria competitively consume vitamin B12 (cobalamin) and convert it into inactive analogues that block host ileal receptors.
• Discordant vitamin patterns: While B12 is depleted, bacterial de novo synthesis pathways actively produce folate (vitamin B9), which is assimilated by the host. This frequently creates a discordant clinical presentation of depressed serum B12 alongside normal or elevated folate levels.

Diagnostic utility of urinary organic acids

• Validated fungal marking: Urinary D-arabinitol is a scientifically validated marker of Candida overgrowth. Its clinical utility is highest when assessed as an enantioselective D-arabinitol to L-arabinitol (D/L) ratio, showing high sensitivity and specificity for significant yeast burden.
• Plausible bacterial and yeast marking: Urinary citramalic acid is produced by intestinal anaerobes and yeasts like Saccharomyces, whereas human cells produce negligible amounts. However, it lacks robust clinical validation, sensitivity/specificity data, and consensus guidelines to serve as a standalone diagnostic biomarker.

Bottom line

• Gut microbial overgrowth characteristically impairs B-vitamin availability by depleting cobalamin while elevating folate. To assess associated dysbiosis, urinary D-arabinitol (specifically the D/L ratio) serves as a robust marker for Candida overgrowth, while urinary citramalic acid remains a biochemically plausible but clinically unvalidated marker.